A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

Vandana G AbramsonMafalda OliveiraAndrés CervantesHans WildiersManish R PatelTodd M BauerPhilippe L BedardCarlos BecerraStephen RicheyMichael C WeiEric ReynerJohn BondNa CuiTimothy R WilsonHeather M MooreCristina SauraIan E Krop

Published in: Breast cancer research and treatment (2019)

Taselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit-risk profile was deemed not advantageous. Further development is not planned.

Keyphrases

metastatic breast cancer
locally advanced
open label
rectal cancer
phase ii study
neoadjuvant chemotherapy
squamous cell carcinoma
clinical trial
radiation therapy
phase ii
phase iii
randomized controlled trial
study protocol